Novoeight® (antihemophilic factor, recombinant)
for Hemophilia

Novoeight is a recombinant factor VIII therapy used to prevent and control bleeding episodes in people with hemophilia A. It is also given before surgery to reduce bleeding risk. Novoeight temporarily replaces missing factor VIII, supporting blood clotting and helping to prevent prolonged or spontaneous bleeding, particularly in joints and muscles.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Hemophilia